Published in Prostaglandins Leukot Essent Fatty Acids on April 01, 2002
Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. J Altern Complement Med (2013) 1.38
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology (2008) 2.31
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24
Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry (2005) 2.18
Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2009) 1.96
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90
Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord (2009) 1.90
Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry (2004) 1.89
Default mode network abnormalities in bipolar disorder and schizophrenia. Psychiatry Res (2010) 1.84
Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry (2006) 1.69
Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. Neuropsychopharmacology (2011) 1.68
Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry (2004) 1.65
Myelin and axon abnormalities in schizophrenia measured with magnetic resonance imaging techniques. Biol Psychiatry (2013) 1.64
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett (2005) 1.60
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 1.58
CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) (2011) 1.57
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry (2005) 1.57
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett (2006) 1.55
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry (2005) 1.48
Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr Serv (2005) 1.43
Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther (2009) 1.42
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res (2009) 1.40
Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry (2010) 1.38
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology (2009) 1.36
The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry (2008) 1.31
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry (2006) 1.24
A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A (2006) 1.23
Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. J Neurosci (2006) 1.22
Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry (2005) 1.20
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol (2010) 1.19
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res (2009) 1.18
Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry (2004) 1.18
Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol (2007) 1.16
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem (2007) 1.15
Gait unsteadiness and fall risk in two affective disorders: a preliminary study. BMC Psychiatry (2004) 1.14
8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor. Beilstein J Org Chem (2007) 1.14
T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn Reson Med (2010) 1.13
Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res (2009) 1.11
Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet (2002) 1.11
Low-field magnetic stimulation in bipolar depression using an MRI-based stimulator. Am J Psychiatry (2004) 1.10
Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry (2011) 1.10
A cross-national relationship between sugar consumption and major depression? Depress Anxiety (2002) 1.07
Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder. Bipolar Disord (2005) 1.07
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul (2010) 1.07
Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology (2008) 1.07
A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res Opin (2011) 1.04
Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res (2003) 1.04
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporter. Ann Med (2005) 1.02
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) (2010) 1.00
Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence. Neuropharmacology (2009) 1.00
Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology (2010) 1.00
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem (2008) 0.99
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy. J Pharmacol Exp Ther (2007) 0.98
Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry (2004) 0.98
Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disord (2005) 0.98
Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol Psychiatry (2007) 0.97
Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology (2012) 0.97
Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology (2013) 0.97
Role of the bed nucleus of the stria terminalis (BST) in the expression of conditioned fear. Ann N Y Acad Sci (2006) 0.96
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95
31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression. Int J Geriatr Psychiatry (2009) 0.95
Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry (2008) 0.95
A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol (2012) 0.94
Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic. Neuropsychopharmacology (2012) 0.93
Functional connectivity of left Heschl's gyrus in vulnerability to auditory hallucinations in schizophrenia. Schizophr Res (2012) 0.93
Current suicide ideation and prior suicide attempts of bipolar patients as influences on caregiver burden. Suicide Life Threat Behav (2007) 0.92
Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Ann Gen Hosp Psychiatry (2004) 0.92
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol (2012) 0.92
Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo. Biol Psychiatry (2011) 0.91
A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. PLoS Genet (2013) 0.91
Comprehensive review of factors implicated in the heterogeneity of response in depression. Depress Anxiety (2012) 0.91
Water and metabolite transverse T2 relaxation time abnormalities in the white matter in schizophrenia. Schizophr Res (2012) 0.91
Brain metabolite concentrations across cortical regions in healthy adults. Brain Res (2010) 0.91
Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses. Schizophr Res (2011) 0.90
Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed (2010) 0.90
Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res (2006) 0.90
Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans. Neuropsychopharmacology (2009) 0.90
Creatine kinase and ATP synthase reaction rates in human frontal lobe measured by ³¹P magnetization transfer spectroscopy at 4T. Magn Reson Imaging (2012) 0.89
Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy (2004) 0.89
Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Curr Med Res Opin (2011) 0.88
Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology (2009) 0.87
Overweight and obesity in bipolar disorders. J Psychiatr Res (2006) 0.87
Cerebellar blood volume in bipolar patients correlates with medication. Biol Psychiatry (2002) 0.87
Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry (2008) 0.87
Oral choline increases choline metabolites in human brain. Psychiatry Res (2004) 0.86
A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord (2008) 0.86